PL230179B1 - N3 Alkilowane pochodne benzoimidazolu, kompozycja je zawierająca oraz ich zastosowanie do wytwarzania leku do leczenia zaburzeń hiperproliferacyjnych - Google Patents

N3 Alkilowane pochodne benzoimidazolu, kompozycja je zawierająca oraz ich zastosowanie do wytwarzania leku do leczenia zaburzeń hiperproliferacyjnych

Info

Publication number
PL230179B1
PL230179B1 PL377628A PL37762803A PL230179B1 PL 230179 B1 PL230179 B1 PL 230179B1 PL 377628 A PL377628 A PL 377628A PL 37762803 A PL37762803 A PL 37762803A PL 230179 B1 PL230179 B1 PL 230179B1
Authority
PL
Poland
Prior art keywords
fluoro
bromo
mmol
benzoimidazol
chlorophenylamino
Prior art date
Application number
PL377628A
Other languages
English (en)
Polish (pl)
Other versions
PL377628A1 (pl
Inventor
Eli M. Wallace
Joseph P. Lyssikatos
Brian T. Hurley
Allison L. Marlow
Original Assignee
Array Biopharma Inc
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=28041856&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL230179(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Array Biopharma Inc, Astrazeneca Ab filed Critical Array Biopharma Inc
Publication of PL377628A1 publication Critical patent/PL377628A1/pl
Publication of PL230179B1 publication Critical patent/PL230179B1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/08—Radicals containing only hydrogen and carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
PL377628A 2002-03-13 2003-03-13 N3 Alkilowane pochodne benzoimidazolu, kompozycja je zawierająca oraz ich zastosowanie do wytwarzania leku do leczenia zaburzeń hiperproliferacyjnych PL230179B1 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36400702P 2002-03-13 2002-03-13
US60/364,007 2002-03-13
PCT/US2003/007864 WO2003077914A1 (en) 2002-03-13 2003-03-13 N3 alkylated benzimidazole derivatives as mek inhibitors

Publications (2)

Publication Number Publication Date
PL377628A1 PL377628A1 (pl) 2006-02-06
PL230179B1 true PL230179B1 (pl) 2018-09-28

Family

ID=28041856

Family Applications (5)

Application Number Title Priority Date Filing Date
PL377628A PL230179B1 (pl) 2002-03-13 2003-03-13 N3 Alkilowane pochodne benzoimidazolu, kompozycja je zawierająca oraz ich zastosowanie do wytwarzania leku do leczenia zaburzeń hiperproliferacyjnych
PL401636A PL233493B1 (pl) 2002-03-13 2003-03-13 Związek benzoimidazolowy, jego zastosowanie oraz zawierająca go kompozycja farmaceutyczna
PL401637A PL401637A1 (pl) 2002-03-13 2003-03-13 N3 alkilowane pochodne benzimidazolu jako inhibitory MEK
PL401635A PL233177B1 (pl) 2002-03-13 2003-03-13 (2-hydroksyetoksy)amid kwasu 6-(4-bromo-2-chlorofenyloamino)- 7-fluoro-3-metylo-3H-benzimidazolo-5-karboksylowego, zawierająca ten związek kompozycja farmaceutyczna oraz ich zastosowanie
PL401638A PL401638A1 (pl) 2002-03-13 2003-03-13 N3 alkilowane pochodne benzimidazolu jako inhibitory MEK

Family Applications After (4)

Application Number Title Priority Date Filing Date
PL401636A PL233493B1 (pl) 2002-03-13 2003-03-13 Związek benzoimidazolowy, jego zastosowanie oraz zawierająca go kompozycja farmaceutyczna
PL401637A PL401637A1 (pl) 2002-03-13 2003-03-13 N3 alkilowane pochodne benzimidazolu jako inhibitory MEK
PL401635A PL233177B1 (pl) 2002-03-13 2003-03-13 (2-hydroksyetoksy)amid kwasu 6-(4-bromo-2-chlorofenyloamino)- 7-fluoro-3-metylo-3H-benzimidazolo-5-karboksylowego, zawierająca ten związek kompozycja farmaceutyczna oraz ich zastosowanie
PL401638A PL401638A1 (pl) 2002-03-13 2003-03-13 N3 alkilowane pochodne benzimidazolu jako inhibitory MEK

Country Status (35)

Country Link
US (11) US20030232869A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (5) EP2275102B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (4) JP4093966B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (3) KR100984613B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (4) CN101633645B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AR (3) AR038971A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE449605T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (2) AU2003218157C1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BE (1) BE2019C510I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BR122018007328B8 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2478374C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CL (2) CL2012002381A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CY (3) CY1109727T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE60330227D1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (4) DK2275102T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DO (4) DOP2003000613A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (5) ES2335276T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR (1) FR19C1014I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (2) HUE025767T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (4) IL163995A0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IS (4) IS2748B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
LT (1) LTC1482932I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
LU (1) LUC00100I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MXPA04008893A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NL (1) NL300974I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ535158A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PA (1) PA8569301A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (5) PL230179B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (4) PT2275102E (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SG (3) SG2013013339A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SI (4) SI2275102T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW (3) TWI350285B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
UA (1) UA77765C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2003077914A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA200407220B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (258)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7235537B2 (en) * 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
PL230179B1 (pl) 2002-03-13 2018-09-28 Array Biopharma Inc N3 Alkilowane pochodne benzoimidazolu, kompozycja je zawierająca oraz ich zastosowanie do wytwarzania leku do leczenia zaburzeń hiperproliferacyjnych
US20060084682A1 (en) * 2002-12-13 2006-04-20 Heerding Dirk A Thrombopoietin mimetics
US20060140872A1 (en) * 2003-02-26 2006-06-29 Kowa Co., Ltd. Novel signaling pathway for the production of inglammatory pain and neuropathy
EP1651214B1 (en) 2003-07-24 2009-09-16 Warner-Lambert Company LLC Benzimidazole derivatives as mek inhibitors
US7144907B2 (en) * 2003-09-03 2006-12-05 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
US7538120B2 (en) * 2003-09-03 2009-05-26 Array Biopharma Inc. Method of treating inflammatory diseases
BRPI0414581C1 (pt) 2003-09-22 2021-05-25 Mei Pharma Inc composto, composição farmacêutica compreendendo o referido composto e uso do referido composto
US7517994B2 (en) 2003-11-19 2009-04-14 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
KR101190912B1 (ko) 2003-11-19 2012-10-12 어레이 바이오파마 인크. Ｍｅｋ의 헤테로시클릭 억제제 및 그의 사용 방법
US7732616B2 (en) * 2003-11-19 2010-06-08 Array Biopharma Inc. Dihydropyridine and dihydropyridazine derivatives as inhibitors of MEK and methods of use thereof
CN1882347A (zh) * 2003-11-21 2006-12-20 阿雷生物药品公司 Akt蛋白激酶抑制剂
US20050171182A1 (en) * 2003-12-11 2005-08-04 Roger Briesewitz Methods and compositions for use in the treatment of mutant receptor tyrosine kinase driven cellular proliferative diseases
AU2005298932B2 (en) 2004-10-20 2012-03-22 Merck Serono Sa 3-arylamino pyridine derivatives
CA2586796A1 (en) * 2004-12-01 2006-06-08 Laboratoires Serono S.A. [1,2,4]triazolo[4,3-a]pyridine derivatives for the treatment of hyperproliferative diseases
US7429667B2 (en) 2005-01-20 2008-09-30 Ardea Biosciences, Inc. Phenylamino isothiazole carboxamidines as MEK inhibitors
ATE539064T1 (de) 2005-05-18 2012-01-15 Array Biopharma Inc Heterozyklische inhibitoren von mek und verwendungsverfahren damit
CA2612419C (en) * 2005-06-23 2017-06-13 Array Biopharma Inc. Process for preparing benzimidazole compounds
CN101247806B (zh) * 2005-06-23 2012-05-16 阵列生物制药公司 用于制备苯并咪唑化合物的SNAr方法
US8101799B2 (en) 2005-07-21 2012-01-24 Ardea Biosciences Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK
AU2013203939B2 (en) * 2005-10-07 2015-08-13 Exelixis, Inc. Azetidines as MEK inhibitors for the treatment of proliferative diseases
AU2012261703B2 (en) * 2005-10-07 2015-08-13 Exelixis, Inc. Azetidines as MEK inhibitors for the treatment of proliferative diseases
PL1934174T3 (pl) * 2005-10-07 2011-09-30 Exelixis Inc Azetydyny jako inhibitory w leczeniu chorób proliferacyjnych
US7572460B2 (en) * 2005-10-25 2009-08-11 Rodrigo Rodriguez-Kabana Hydrogen cyanamide pesticide formulations
US7968108B2 (en) * 2005-10-25 2011-06-28 Metbro Distributing L.P. Hydrogen cyanamide pesticide formulations
WO2007071951A1 (en) * 2005-12-21 2007-06-28 Astrazeneca Ab Tosylate salt of 6- (4-br0m0-2-chl0r0phenylamin0) -7-fluoro-n- (2-hydroxyethoxy) -3-methyl-3h-benzimi dazole- 5 - carboxamide , mek inhibitor useful in the treatment of cancer
TWI405756B (zh) * 2005-12-21 2013-08-21 Array Biopharma Inc 新穎硫酸氫鹽
RU2418790C3 (ru) * 2005-12-21 2022-03-14 Астразенека Аб Новая гидросульфатная соль
CA2534243A1 (fr) 2006-01-25 2007-07-25 Hydro Quebec Particules d'oxyde metallique enrobees a faible taux de dissolution, procedes de preparation et utilisation dans les systemes electrochimiques
GB0601962D0 (en) 2006-01-31 2006-03-15 Ucb Sa Therapeutic agents
WO2007121269A2 (en) 2006-04-11 2007-10-25 Ardea Biosciences, Inc. N-aryl-n'alkyl sulfamides as mek inhibitors
ATE483463T1 (de) * 2006-04-18 2010-10-15 Ardea Biosciences Inc Pyridonsulfonamide und pyridonsulfamide als mek- hemmer
HRP20110882T1 (hr) 2006-07-06 2012-01-31 Array Biopharma Ciklopenta [d] pirimidini kao inhibitori kinaze akt proteina
US8063050B2 (en) 2006-07-06 2011-11-22 Array Biopharma Inc. Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
ATE532789T1 (de) 2006-07-06 2011-11-15 Array Biopharma Inc Dihydrothienopyrimidine als akt-proteinkinase- inhibitoren
CN101511842B (zh) 2006-07-06 2012-10-31 阵列生物制药公司 作为akt蛋白激酶抑制剂的二氢呋喃并嘧啶
WO2008016123A1 (fr) * 2006-08-03 2008-02-07 Takeda Pharmaceutical Company Limited INHIBITEUR DE LA GSK-3β
ZA200901009B (en) * 2006-08-21 2010-05-26 Genentech Inc Aza-benzothiophenyl compounds and methods of use
EP2069359B1 (en) 2006-08-21 2014-11-12 Genentech, Inc. Aza-benzothiophenyl compounds and methods of use
ES2376771T3 (es) * 2006-08-21 2012-03-16 Genentech, Inc. Compuestos aza-benzofuranilo y métodos de utilización
AU2007334402B2 (en) 2006-12-14 2014-02-13 Exelixis, Inc. Methods of using MEK inhibitors
JO2985B1 (ar) 2006-12-20 2016-09-05 Takeda Pharmaceuticals Co مثبطات كينازmapk/erk
CN101678001A (zh) * 2007-04-13 2010-03-24 阿斯利康(瑞典)有限公司 包含azd2171和azd6244或mek-抑制剂ⅱ的组合治疗
US8509487B2 (en) * 2007-04-19 2013-08-13 Avago Technologies General Ip (Singapore) Pte. Ltd. System and method for optically measuring a parameter of an object
WO2008157179A2 (en) 2007-06-12 2008-12-24 Genentech, Inc. N-substituted azaindoles and methods of use
BRPI0813999A2 (pt) 2007-07-05 2019-10-01 Array Biopharma Inc ciclopentanos de pirimidil como inibidores de akt proteína cinase
US8846683B2 (en) 2007-07-05 2014-09-30 Array Biopharma, Inc. Pyrimidyl cyclopentanes as Akt protein kinase inhibitors
US9409886B2 (en) 2007-07-05 2016-08-09 Array Biopharma Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
KR101624361B1 (ko) * 2007-07-05 2016-05-25 어레이 바이오파마 인크. Ａｋｔ 단백질 키나제 억제제로서의 피리미딜 시클로펜탄
GB0714384D0 (en) 2007-07-23 2007-09-05 Ucb Pharma Sa theraputic agents
KR20100089082A (ko) * 2007-10-15 2010-08-11 아스트라제네카 아베 조합 059
CA2705452C (en) 2007-11-12 2016-05-31 Takeda Pharmaceutical Company Limited Mapk/erk kinase inhibitors
AU2008343065B2 (en) 2007-12-19 2012-04-05 Genentech, Inc. 5-anilinoimidazopyridines and methods of use
DK2231662T3 (da) 2007-12-19 2011-08-29 Genentech Inc 8-Anilinoimidazopyridiner og deres anvendelse som anticancer- og/eller antiinflammatoriske midler
KR20100086503A (ko) 2007-12-20 2010-07-30 에프. 호프만-라 로슈 아게 Ｍｅｋ 키나아제 저해제로서의 치환된 히단토인
NZ586575A (en) 2007-12-21 2012-03-30 Genentech Inc Azaindolizines and methods of use
EP2240455B1 (en) * 2008-01-09 2012-12-26 Array Biopharma, Inc. Hydroxylated pyrimidyl cyclopentane as akt protein kinase inhibitor
EP2247578B1 (en) * 2008-01-09 2013-05-22 Array Biopharma, Inc. Hydroxylated pyrimidyl cyclopentanes as akt protein kinase inhibitors
WO2009093008A1 (en) 2008-01-21 2009-07-30 Ucb Pharma S.A. Thieno-pyridine derivatives as mek inhibitors
SA109300195B1 (ar) 2008-03-28 2013-04-20 Astrazeneca Ab تركيبة صيدلانية جديدة مضادة للسرطان
GB0811304D0 (en) 2008-06-19 2008-07-30 Ucb Pharma Sa Therapeutic agents
US8559963B2 (en) 2008-06-23 2013-10-15 Panasonic Corporation Wireless communication base station apparatus and reference signal allocation method
CA2727250A1 (en) 2008-07-01 2010-01-07 Genentech, Inc. Bicyclic heterocycles as mek kinase inhibitors
WO2010003022A1 (en) 2008-07-01 2010-01-07 Genentech, Inc. Isoindolone derivatives as mek kinase inhibitors and methods of use
MY151342A (en) 2008-08-04 2014-05-15 Merck Patent Gmbh Phenylamino isonicotinamide compounds
CN101653607B (zh) * 2008-08-19 2013-02-13 鼎泓国际投资（香港）有限公司 含有肝细胞生长因子受体抑制剂和丝裂原细胞外激酶抑制剂的药物组合物及其用途
US8470819B2 (en) * 2008-11-03 2013-06-25 Merck Sharp & Dohme Corp. Benzimidazole and aza-benzimidazole carboxamides
ES2399384T3 (es) 2008-11-10 2013-04-01 Bayer Schering Pharma Ag Sulfonamido fenoxibenzamidas sustituidas
AR077975A1 (es) 2009-08-28 2011-10-05 Irm Llc Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina
US8242260B2 (en) 2009-08-28 2012-08-14 Novartis Ag Compounds and compositions as protein kinase inhibitors
CN102574782B (zh) 2009-10-21 2014-10-08 拜耳知识产权有限责任公司 取代的卤代苯氧基苯甲酰胺衍生物
CN102656142A (zh) 2009-10-21 2012-09-05 拜耳制药股份公司 取代的苯磺酰胺
US20120269803A1 (en) 2009-10-21 2012-10-25 Bayer Intellectual Property Gmbh Substituted benzosulphonamides
WO2011095807A1 (en) 2010-02-07 2011-08-11 Astrazeneca Ab Combinations of mek and hh inhibitors
EP2560640A1 (en) 2010-04-19 2013-02-27 Synta Pharmaceuticals Corp. Cancer therapy using a combination of a hsp90 inhibitory compounds and a egfr inhibitor
JP5945532B2 (ja) 2010-04-21 2016-07-05 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤としてのベンゾイミダゾール誘導体
EP2585454A1 (en) 2010-06-25 2013-05-01 Novartis AG Heteroaryl compounds and compositions as protein kinase inhibitors
KR20130113430A (ko) 2010-08-05 2013-10-15 케이스 웨스턴 리저브 유니버시티 신경 연결의 발달 장애에 대한 ｅｒｋ 억제제
PH12013500646A1 (en) 2010-10-06 2015-11-13 Glaxosmithkline Llc Benzimidazole derivatives as pi3 kinase inhibitors
EP2632899A1 (en) 2010-10-29 2013-09-04 Bayer Intellectual Property GmbH Substituted phenoxypyridines
CN102020651B (zh) 2010-11-02 2012-07-18 北京赛林泰医药技术有限公司 6-芳基氨基吡啶酮甲酰胺mek抑制剂
CN114164167B (zh) 2010-12-22 2025-02-21 菲特治疗公司 用于单细胞分选与增强ipsc重新编程的细胞培养平台
EP2655375B1 (fr) 2010-12-23 2014-12-03 Sanofi Derives de pyrimidinone, leur preparation et leur utilisation pharmaceutique
SG194048A1 (en) 2011-04-01 2013-11-29 Genentech Inc Combinations of akt inhibitor compounds and chemotherapeutic agents, and methods of use
RU2013148817A (ru) 2011-04-01 2015-05-10 Дженентек, Инк. Комбинации соединений-ингибиторов акт и мек и способы их применения
WO2012145503A1 (en) 2011-04-21 2012-10-26 Novartis Ag Pharmaceutical combinations
US20140228418A1 (en) * 2011-05-23 2014-08-14 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitory compounds with mek inhibitors
US9833439B2 (en) 2011-05-25 2017-12-05 Universite Paris Descartes ERK inhibitors for use in treating spinal muscular atrophy
ES2671748T3 (es) 2011-07-21 2018-06-08 Tolero Pharmaceuticals, Inc. Inhibidores heterocíclicos de proteína quinasas
PH12014500270A1 (en) * 2011-08-01 2014-03-31 Genentech Inc Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors
US10813630B2 (en) 2011-08-09 2020-10-27 Corquest Medical, Inc. Closure system for atrial wall
US10307167B2 (en) 2012-12-14 2019-06-04 Corquest Medical, Inc. Assembly and method for left atrial appendage occlusion
US10314594B2 (en) 2012-12-14 2019-06-11 Corquest Medical, Inc. Assembly and method for left atrial appendage occlusion
WO2013066483A1 (en) 2011-08-31 2013-05-10 Novartis Ag Synergistic combinations of pi3k- and mek-inhibitors
JP2014528928A (ja) * 2011-09-01 2014-10-30 ノバルティス アーゲー ヌーナン症候群の治療のための有機化合物の使用
EP2570127A1 (en) 2011-09-16 2013-03-20 Sanofi Compositions and methods for treating cancer using PI3KB beta inhibitor and MAPK pathway inhibitor, including MEK and RAF inhibitors
WO2013056183A1 (en) 2011-10-14 2013-04-18 Array Biopharma Inc. Polymorphs of arry-380, a selective herb2 inhibitor and pharmaceutical compositions contianing them
CA2853799A1 (en) 2011-11-02 2013-05-10 Synta Pharmaceuticals Corp. Cancer therapy using a combination of hsp90 inhibitors with topoisomerase i inhibitors
WO2013067165A1 (en) 2011-11-02 2013-05-10 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitors with platinum-containing agents
WO2013074594A1 (en) 2011-11-14 2013-05-23 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitors with braf inhibitors
CN108424456B (zh) 2011-11-23 2022-04-26 医学免疫有限责任公司 特异于her3的结合分子及其用途
WO2013082511A1 (en) 2011-12-02 2013-06-06 Genentech, Inc. Methods for overcoming tumor resistance to vegf antagonists
CN104302768A (zh) 2012-01-09 2015-01-21 诺华股份有限公司 治疗β-联蛋白相关疾病的有机组合物
WO2013109142A1 (en) 2012-01-16 2013-07-25 Stichting Het Nederlands Kanker Instituut Combined pdk and mapk/erk pathway inhibition in neoplasia
CN103204827B (zh) 2012-01-17 2014-12-03 上海科州药物研发有限公司 作为蛋白激酶抑制剂的苯并噻二唑化合物及其制备方法和用途
GB201201332D0 (en) 2012-01-26 2012-03-14 Imp Innovations Ltd Method
US8961970B2 (en) 2012-03-20 2015-02-24 Novartis Ag Combination therapy
WO2013152425A1 (en) 2012-04-09 2013-10-17 Switch Materials , Inc. Switching materials, and compositions and methods for making same
JP6463673B2 (ja) 2012-05-29 2019-02-06 スイッチ マテリアルズ インコーポレイテッドＳｗｉｔｃｈ Ｍａｔｅｒｉａｌｓ Ｉｎｃ． 可変透過率層を含む光学フィルタ
MX2014014097A (es) 2012-05-31 2015-04-13 Bayer Pharma AG Biomarcadores para determinar la respuesta eficaz de tratamientos en pacientes de carcinoma hepatocelular (chc).
AR091876A1 (es) * 2012-07-26 2015-03-04 Novartis Ag Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas
WO2014027056A1 (en) 2012-08-17 2014-02-20 F. Hoffmann-La Roche Ag Combination therapies for melanoma comprising administering cobimetinib and vemurafinib
SMT201700109T1 (it) 2012-10-02 2017-03-08 Gilead Sciences Inc Inibitori di istone demetilasi
JP6300042B2 (ja) 2012-10-12 2018-03-28 エグゼリクシス， インコーポレイテッド 癌の処置に使用するための化合物の製造方法
US9394257B2 (en) 2012-10-16 2016-07-19 Tolero Pharmaceuticals, Inc. PKM2 modulators and methods for their use
SI3702351T1 (sl) * 2012-10-19 2024-03-29 Array Biopharma Inc., Formulacija, ki obsega inhibitor mek
US20140142689A1 (en) 2012-11-21 2014-05-22 Didier De Canniere Device and method of treating heart valve malfunction
JP6437444B2 (ja) * 2012-11-29 2018-12-12 ノバルティス アーゲー 医薬的組合せ
US9867825B2 (en) 2012-12-20 2018-01-16 Novartis Ag Pharmaceutical combination comprising binimetinib
EP2752191A1 (en) 2013-01-07 2014-07-09 Sanofi Compositions and methods using hdm2 antagonist and mek inhibitor
US20140242595A1 (en) 2013-02-22 2014-08-28 Cellular Dynamics International, Inc. Hepatocyte production via forward programming by combined genetic and chemical engineering
SI2961736T1 (en) 2013-02-27 2018-06-29 Gilead Sciences, Inc. Histone demethylase inhibitors
ES2703208T3 (es) 2013-02-27 2019-03-07 Daiichi Sankyo Co Ltd Método de predicción de la sensibilidad a un compuesto que inhibe la vía de transducción de señales de MAPK
KR102334260B1 (ko) 2013-03-14 2021-12-02 스미토모 다이니폰 파마 온콜로지, 인크. Ｊａｋ2 및 ａｌｋ2 억제제 및 이들의 사용 방법
CN112641787A (zh) 2013-03-21 2021-04-13 诺华股份有限公司 包含B-Raf抑制剂和第二抑制剂的组合疗法
AR097617A1 (es) 2013-09-13 2016-04-06 Actelion Pharmaceuticals Ltd Derivados antibacterianos del 2h-indazol
US9629851B2 (en) 2013-09-20 2017-04-25 Stitching Het Nederlands Kanker Institut—Antoni Van Leeuwenhoek Ziekenhuis ROCK in combination with MAPK pathway
WO2015041534A1 (en) 2013-09-20 2015-03-26 Stichting Het Nederlands Kanker Instituut P90rsk in combination with raf/erk/mek
EP3049442A4 (en) 2013-09-26 2017-06-28 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
US9566443B2 (en) 2013-11-26 2017-02-14 Corquest Medical, Inc. System for treating heart valve malfunction including mitral regurgitation
TR201807881T4 (tr) 2013-12-19 2018-06-21 Idorsia Pharmaceuticals Ltd Antibakteriyel 1h-ındazol ve 1h-ındol türevleri.
US20160340407A1 (en) 2014-01-14 2016-11-24 Dana-Farber Camcer Institute, Inc. Compositions and methods for identification, assessment, prevention, and treatment of melanoma using pd-l1 isoforms
CN104788365B (zh) * 2014-01-16 2018-08-10 上海艾力斯医药科技有限公司 异烟酰胺衍生物、其制备方法及应用
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
JP6722108B2 (ja) 2014-03-04 2020-07-15 フェイト セラピューティクス，インコーポレイテッド 改善された再プログラム方法及び細胞培養基盤
AR099612A1 (es) 2014-03-04 2016-08-03 Actelion Pharmaceuticals Ltd Derivados antibacterianos de 1,2-dihidro-3h-pirrolo[1,2-c]imidazol-3-ona
CU24481B1 (es) 2014-03-14 2020-03-04 Immutep Sas Moléculas de anticuerpo que se unen a lag-3
US20170369444A1 (en) 2014-03-31 2017-12-28 Marc Labelle Inhibitors of histone demethylases
US20170107486A1 (en) 2014-04-21 2017-04-20 Cellular Dynamics International, Inc. Hepatocyte production via forward programming by combined genetic and chemical engineering
WO2015173329A1 (en) 2014-05-16 2015-11-19 Actelion Pharmaceuticals Ltd Antibacterial quinazoline-4(3h)-one derivatives
US10023879B2 (en) 2014-06-04 2018-07-17 Fate Therapeutics, Inc. Minimal volume reprogramming of mononuclear cells
ES2742500T3 (es) 2014-07-15 2020-02-14 Federal Express Corp Composiciones para tratamiento del cáncer usando antagonistas de unión al eje de pd-1 e inhibidores de MEK
US9802941B2 (en) 2014-08-27 2017-10-31 Gilead Sciences, Inc. Compounds and methods for inhibiting histone demethylases
EP3191127A1 (en) 2014-09-13 2017-07-19 Novartis AG Combination therapies of egfr inhibitors
AU2015327868A1 (en) 2014-10-03 2017-04-20 Novartis Ag Combination therapies
US20170248603A1 (en) 2014-10-06 2017-08-31 Dana-Farber Cancer Institute, Inc. Angiopoiten-2 biomarkers predictive of anti-immune checkpoint response
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
MA40035A (fr) 2014-10-14 2016-04-21 Dana Farber Cancer Inst Inc Molécules d'anticorps de pd-l1 et leurs utilisations
US10842626B2 (en) 2014-12-09 2020-11-24 Didier De Canniere Intracardiac device to correct mitral regurgitation
WO2016100882A1 (en) 2014-12-19 2016-06-23 Novartis Ag Combination therapies
ME03385B (me) 2014-12-23 2020-01-20 Novartis Ag Triazolopirimidin jedinjenja i njihova upotreba
US10626372B1 (en) 2015-01-26 2020-04-21 Fate Therapeutics, Inc. Methods and compositions for inducing hematopoietic cell differentiation
CN105566225A (zh) * 2015-02-16 2016-05-11 苏州晶云药物科技有限公司 一种口服丝裂原活化蛋白激酶抑制剂的晶型及其制备方法
JP2016155776A (ja) * 2015-02-24 2016-09-01 学校法人兵庫医科大学 抗腫瘍効果増強剤および抗腫瘍剤
MA42146A (fr) 2015-03-10 2021-04-21 Aduro Biotech Inc Compositions et procédés d'activation de la signalisation dépendante de « stimulateur de gènes d'interféron »
JP6695353B2 (ja) 2015-03-25 2020-05-20 ノバルティス アーゲー Ｆｇｆｒ４阻害剤としてのホルミル化ｎ−複素環式誘導体
MA41866A (fr) 2015-03-31 2018-02-06 Massachusetts Gen Hospital Molécules à auto-assemblage pour l'administration ciblée de médicaments
ES2878188T3 (es) 2015-07-29 2021-11-18 Novartis Ag Terapias de combinación que comprenden moléculas de anticuerpos contra LAG-3
US20180207273A1 (en) 2015-07-29 2018-07-26 Novartis Ag Combination therapies comprising antibody molecules to tim-3
US20180222982A1 (en) 2015-07-29 2018-08-09 Novartis Ag Combination therapies comprising antibody molecules to pd-1
AR105646A1 (es) 2015-08-11 2017-10-25 Actelion Pharmaceuticals Ltd Agentes antibacterianos de 1,2-dihidro-3h-pirrolo[1,2-c]imidazol-3-ona sustituida
WO2017033113A1 (en) 2015-08-21 2017-03-02 Acerta Pharma B.V. Therapeutic combinations of a mek inhibitor and a btk inhibitor
CN108348520A (zh) 2015-08-28 2018-07-31 诺华股份有限公司 Mdm2抑制剂和其组合
AR105889A1 (es) 2015-09-03 2017-11-22 Actelion Pharmaceuticals Ltd Compuestos antibacterianos 1,2-dihidro-3h-pirrolo[1,2-c]imidazol-3-ona sustituidos
CN117737124A (zh) 2015-10-16 2024-03-22 菲特治疗公司 用于诱导和维护基态多能性的平台
MX2018005551A (es) 2015-11-03 2018-11-09 Janssen Biotech Inc Anticuerpos que se unen especificamente a pd-1, y sus usos.
AU2016349504B2 (en) 2015-11-04 2023-02-09 Fate Therapeutics, Inc. Genomic engineering of pluripotent cells
WO2017078807A1 (en) 2015-11-04 2017-05-11 Fate Therapeutics, Inc. Methods and compositions for inducing hematopoietic cell differentiation
BR112018012138A2 (pt) 2015-12-17 2018-12-04 Novartis Ag moléculas de anticorpo para pd-1 e usos das mesmas
CA3010236A1 (en) 2016-01-20 2017-07-27 Fate Therapeutics, Inc. Compositions and methods for immune cell modulation in adoptive immunotherapies
WO2017127755A1 (en) 2016-01-20 2017-07-27 Fate Therapeutics, Inc. Compositions and methods for immune cell modulation in adoptive immunotherapies
WO2017150725A1 (ja) 2016-03-04 2017-09-08 大鵬薬品工業株式会社 悪性腫瘍治療用製剤及び組成物
US11883404B2 (en) 2016-03-04 2024-01-30 Taiho Pharmaceuticals Co., Ltd. Preparation and composition for treatment of malignant tumors
AR108257A1 (es) 2016-05-02 2018-08-01 Mei Pharma Inc Formas polimórficas de 3-[2-butil-1-(2-dietilamino-etil)-1h-bencimidazol-5-il]-n-hidroxi-acrilamida y usos de las mismas
RU2759669C2 (ru) 2016-06-03 2021-11-16 Аррэй Байофарма Инк. Фармацевтические комбинации
ES2798424T3 (es) 2016-06-20 2020-12-11 Novartis Ag Compuestos de triazolopiridina y usos de estos
US11091489B2 (en) 2016-06-20 2021-08-17 Novartis Ag Crystalline forms of a triazolopyrimidine compound
JP2019524872A (ja) 2016-06-20 2019-09-05 ノバルティス アーゲー 癌の治療に有用なイミダゾピリミジン化合物
EP3507367A4 (en) 2016-07-05 2020-03-25 Aduro BioTech, Inc. CYCLIC DINUCLEOTID COMPOUNDS WITH INCLUDED NUCLEIC ACIDS AND USES THEREOF
WO2018065924A1 (en) * 2016-10-04 2018-04-12 Sun Pharmaceutical Industries Limited Intermediates of mitogen-activated protein kinase kinase (map2k or mek) inhibitors and process for their preparation
WO2018092064A1 (en) 2016-11-18 2018-05-24 Novartis Ag Combinations of mdm2 inhibitors and bcl-xl inhibitors
CN108084078B (zh) * 2016-11-24 2021-07-30 中山大学 一种治疗银屑病性关节炎疾病的药物阿普斯特的合成方法
US11932870B2 (en) 2016-12-05 2024-03-19 Fate Therapeutics, Inc. Compositions and methods for immune cell modulation in adoptive immunotherapies
EP3372624A1 (en) 2017-03-06 2018-09-12 Henkel AG & Co. KGaA One component composition based on compounds with at least two exo-vinylene cyclic carbonate units
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
WO2019096112A1 (zh) * 2017-11-14 2019-05-23 深圳市塔吉瑞生物医药有限公司 一种取代的苯并咪唑化合物及包含该化合物的组合物
RU2020119578A (ru) 2017-11-16 2021-12-17 Новартис Аг Комбинированные терапии
TW201938165A (zh) 2017-12-18 2019-10-01 美商輝瑞股份有限公司 治療癌症的方法及組合療法
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
EP4353222A1 (en) 2018-03-19 2024-04-17 Taiho Pharmaceutical Co., Ltd. Use of sodium alkyl sulfate
WO2019195753A1 (en) 2018-04-05 2019-10-10 Tolero Pharmaceuticals, Inc. Axl kinase inhibitors and use of the same
AU2019274657A1 (en) 2018-05-24 2020-12-10 Janssen Biotech, Inc. PSMA binding agents and uses thereof
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
WO2020021465A1 (en) 2018-07-25 2020-01-30 Advanced Accelerator Applications (Italy) S.R.L. Method of treatment of neuroendocrine tumors
DE202018006567U1 (de) 2018-07-25 2021-02-22 Advanced Accelerator Applications Sa Stabile, konzentrierte Radionuklidkomplexlösungen
CA3103995A1 (en) 2018-07-26 2020-01-30 Sumitomo Dainippon Pharma Oncology, Inc. Methods for treating diseases associated with abnormal acvr1 expression and acvr1 inhibitors for use in the same
EP4219488A1 (en) 2018-08-17 2023-08-02 Novartis AG Method for the preparation of urea compounds as smarca2/brm-atpase inhibitors
JP7358484B2 (ja) 2018-09-25 2023-10-10 アドヴァンスド・アクセラレーター・アプリケーションズ・（イタリー）・エッセエッレエッレ 併用療法
JP7406264B2 (ja) 2018-11-20 2023-12-27 エヌフレクション セラピューティクス インコーポレイテッド 皮膚障害の処置のためのシアノアリール－アニリン化合物
JP7393808B2 (ja) 2018-11-20 2023-12-07 エヌフレクション セラピューティクス インコーポレイテッド 皮膚障害の処置のためのナフチリジノン－アニリン化合物
US20240245670A1 (en) 2018-12-20 2024-07-25 Novartis Ag Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
BR112021011894A2 (pt) 2018-12-21 2021-09-08 Daiichi Sankyo Company, Limited Composição farmacêutica
CN113412262A (zh) 2019-02-12 2021-09-17 大日本住友制药肿瘤公司 包含杂环蛋白激酶抑制剂的制剂
US20220144798A1 (en) 2019-02-15 2022-05-12 Novartis Ag Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
MX2021009763A (es) 2019-02-15 2021-09-08 Novartis Ag Derivados de 3-(1-oxo-5-(piperidin-4-il)isoindolin-2-il)piperidina -2,6-diona y usos de los mismos.
CA3129665A1 (en) 2019-03-21 2020-09-24 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
MX2021011289A (es) 2019-03-22 2021-11-03 Sumitomo Pharma Oncology Inc Composiciones que comprenden moduladores de isoenzima m2 muscular de piruvato cinasa pkm2 y metodos de tratamiento que usan las mismas.
WO2020212832A1 (en) * 2019-04-16 2020-10-22 Alembic Pharmaceuticals Limited Process of preparation of benzimidazole compounds
EP3956022A1 (en) 2019-04-19 2022-02-23 Janssen Biotech, Inc. Methods of treating prostate cancer with an anti- psma/cd3 antibody
TWI817018B (zh) 2019-06-28 2023-10-01 美商艾瑞生藥股份有限公司 用於治療ｂｒａｆ相關的疾病和失調症之化合物
AU2020300619A1 (en) 2019-07-03 2022-01-27 Sumitomo Pharma Oncology, Inc. Tyrosine kinase non-receptor 1 (TNK1) inhibitors and uses thereof
CN114746414B (zh) 2019-09-26 2024-10-18 诺华公司 氮杂-喹啉化合物及其用途
WO2021089791A1 (en) 2019-11-08 2021-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021116901A1 (en) * 2019-12-09 2021-06-17 Biocon Limited Forms of binimetinib and process for preparation thereof
AU2020410266A1 (en) 2019-12-20 2022-06-30 Novartis Ag Combination of anti TIM-3 antibody MBG453 and anti TGF-beta antibody NIS793, with or without decitabine or the anti PD-1 antibody spartalizumab, for treating myelofibrosis and myelodysplastic syndrome
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
EP4122925A4 (en) * 2020-03-17 2024-04-17 Medshine Discovery Inc. PROTEOLYSIS REGULATOR AND METHOD OF USE
TW202200146A (zh) 2020-04-10 2022-01-01 日商大鵬藥品工業股份有限公司 使用有3,5-二取代苯炔基化合物與mek抑制劑之癌症治療法
JP7312335B2 (ja) 2020-06-09 2023-07-20 アレイ バイオファーマ インコーポレイテッド Ｂｒａｆ関連疾患および障害を処置するための４－オキソ－３，４－ジヒドロキナゾリノン化合物
BR112022026202A2 (pt) 2020-06-23 2023-01-17 Novartis Ag Regime de dosagem compreendendo derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona
AR123185A1 (es) 2020-08-10 2022-11-09 Novartis Ag Compuestos y composiciones para inhibir ezh2
WO2022043556A1 (en) 2020-08-31 2022-03-03 Novartis Ag Stable radiopharmaceutical composition
WO2022043558A1 (en) 2020-08-31 2022-03-03 Advanced Accelerator Applications International Sa Method of treating psma-expressing cancers
WO2022043557A1 (en) 2020-08-31 2022-03-03 Advanced Accelerator Applications International Sa Method of treating psma-expressing cancers
WO2022074011A1 (en) 2020-10-05 2022-04-14 Pierre Fabre Medicament Combination of encorafenib and binimetinib as adjuvant treatment for resected stage ii melanoma
TW202237119A (zh) 2020-12-10 2022-10-01 美商住友製藥腫瘤公司 Ａｌｋ﹘５抑制劑和彼之用途
CN112759552A (zh) * 2020-12-31 2021-05-07 武汉九州钰民医药科技有限公司 司美替尼的合成方法
CN112679438A (zh) * 2020-12-31 2021-04-20 武汉九州钰民医药科技有限公司 制备司美替尼的方法
US12141240B2 (en) 2021-01-20 2024-11-12 Rutgers, The State University Of New Jersey Method of calibration using master calibration function
CN117136056A (zh) * 2021-01-21 2023-11-28 恩福莱克逊治疗有限公司 吡咯并吡啶-苯胺化合物的制备方法
EP4284838A2 (en) 2021-01-28 2023-12-06 Janssen Biotech, Inc. Psma binding proteins and uses thereof
US20250179063A2 (en) 2021-02-02 2025-06-05 Les Laboratoires Servier Selective bcl-xl protac compounds and methods of use
EP4308935A1 (en) 2021-03-18 2024-01-24 Novartis AG Biomarkers for cancer and methods of use thereof
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
WO2022221227A1 (en) 2021-04-13 2022-10-20 Nuvalent, Inc. Amino-substituted heterocycles for treating cancers with egfr mutations
EP4322953A4 (en) * 2021-04-15 2025-01-22 Ideaya Biosciences, Inc. COMBINATION THERAPY WITH A PKC INHIBITOR AND A MEK INHIBITOR
AR125874A1 (es) 2021-05-18 2023-08-23 Novartis Ag Terapias de combinación
CN117642166A (zh) 2021-06-09 2024-03-01 中外制药株式会社 用于癌症治疗的组合疗法
CN115490640B (zh) * 2021-06-17 2024-11-26 深圳市塔吉瑞生物医药有限公司 取代的苯并咪唑类化合物及包含该化合物的组合物及其用途
TW202317546A (zh) 2021-07-09 2023-05-01 美商普萊克斯姆公司 調節ikzf2之芳基化合物及醫藥組合物
EP4426305A1 (en) 2021-11-04 2024-09-11 F. Hoffmann-La Roche AG Novel use of quinazolinone compound for the treatment of cancer
WO2023084489A1 (en) 2021-11-15 2023-05-19 Pfizer Inc. Methods of treating coronavirus disease 2019
TW202342018A (zh) 2022-03-04 2023-11-01 美商奇奈特生物製藥公司 Mek激酶抑制劑
KR20250027281A (ko) 2022-05-20 2025-02-25 노파르티스 아게 Epha2 bcl-xl 억제제 항체-약물 접합체 및 그의 사용 방법
KR20250027282A (ko) 2022-05-20 2025-02-25 노파르티스 아게 Met bcl-xl 억제제 항체-약물 접합체 및 그의 사용 방법
EP4536226A1 (en) * 2022-06-06 2025-04-16 Alivus Life Sciences Limited Process for preparation of selumetinib and salts thereof
CN120265291A (zh) 2022-11-18 2025-07-04 豪夫迈·罗氏有限公司 喹唑啉酮化合物的新用途和制剂
WO2024189481A1 (en) 2023-03-10 2024-09-19 Novartis Ag Panras inhibitor antibody-drug conjugates and methods of use thereof
WO2025073765A1 (en) 2023-10-03 2025-04-10 Institut National de la Santé et de la Recherche Médicale Methods of prognosis and treatment of patients suffering from melanoma
WO2025111450A1 (en) 2023-11-22 2025-05-30 Les Laboratoires Servier Anti-cd74 antibody-drug conjugates and methods of use thereof
FR3159741A1 (fr) 2024-03-04 2025-09-05 Pierre Fabre Medicament Formulation topique comprenant du binimetinib
PL451049A1 (pl) * 2025-01-27 2025-08-04 Politechnika Lubelska Kompozytowa konstrukcja przekładkowa
PL451045A1 (pl) * 2025-01-27 2025-06-09 Politechnika Lubelska Kompozytowa konstrukcja przekładkowa
PL451050A1 (pl) * 2025-01-27 2025-08-04 Politechnika Lubelska Kompozytowa konstrukcja przekładkowa
PL451047A1 (pl) * 2025-01-27 2025-08-18 Politechnika Lubelska Kompozytowa konstrukcja przekładkowa
PL451046A1 (pl) * 2025-01-27 2025-06-09 Politechnika Lubelska Kompozytowa konstrukcja przekładkowa
PL451048A1 (pl) * 2025-01-27 2025-08-04 Politechnika Lubelska Kompozytowa konstrukcja przekładkowa

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1980001113A1 (en) 1978-11-20 1980-05-29 Braun Ag Time-keeper in particular quartz controlled clock
GB8607683D0 (en) 1986-03-27 1986-04-30 Ici Plc Anti-tumor agents
GB8827305D0 (en) 1988-11-23 1988-12-29 British Bio Technology Compounds
US5250554A (en) 1989-10-24 1993-10-05 Takeda Chemical Industries, Ltd. Benzimidazole derivatives useful as angiotensin II inhibitors
IL95975A (en) 1989-10-24 1997-06-10 Takeda Chemical Industries Ltd N-benzyl- 2-alkylbenzimidazole derivatives, their production and pharmaceutical compositions containing them
US5218356A (en) * 1991-05-31 1993-06-08 Guenther Knapp Wireless indoor data relay system
US5216003A (en) 1992-01-02 1993-06-01 G. D. Searle & Co. Diacid-containing benzimidazole compounds for treatment of neurotoxic injury
US5455258A (en) 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
WO1995003286A1 (fr) 1993-07-23 1995-02-02 The Green Cross Corporation Derive de triazole et son utilisation pharmaceutique
EP0639573A1 (de) 1993-08-03 1995-02-22 Hoechst Aktiengesellschaft Benzokondensierte 5-Ringheterocyclen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, ihre Verwendung als Diagnostikum, sowie sie enthaltendes Medikament
EP0694535A1 (en) 1994-04-29 1996-01-31 Eli Lilly And Company Non-peptidyl tachykinin receptor antagonists
US5520187A (en) 1994-11-25 1996-05-28 General Electric Company Ultrasonic probe with programmable multiplexer for imaging systems with different channel counts
US5525625A (en) 1995-01-24 1996-06-11 Warner-Lambert Company 2-(2-Amino-3-methoxyphenyl)-4-oxo-4H-[1]benzopyran for treating proliferative disorders
US5863949A (en) 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
JP3053222B2 (ja) 1995-04-20 2000-06-19 ファイザー・インコーポレーテッド Ｍｍｐおよびｔｎｆ抑制剤としてのアリールスルホニルヒドロキサム酸誘導体
US5972980A (en) 1995-10-05 1999-10-26 Warner-Lambert Company Method for treating and preventing inflammation and atherosclerosis
DE69624081T2 (de) 1995-12-20 2003-06-12 Agouron Pharmaceuticals, Inc. Matrix-metalloprotease Inhibitoren
GB9600344D0 (en) 1996-01-09 1996-03-13 Lilly Co Eli Benzimidzolyl neuropeptide y receptor antagonists
YU1899A (sh) 1996-07-18 2000-03-21 Pfizer Inc. Inhibitori matričnih metaloproteaza na bazi fosfinata
IL128189A0 (en) 1996-08-23 1999-11-30 Pfizer Arylsulfonylamino hydroxamic acid derivatives
US6077864A (en) 1997-01-06 2000-06-20 Pfizer Inc. Cyclic sulfone derivatives
AU721748B2 (en) 1997-02-03 2000-07-13 Pfizer Products Inc. Arylsulfonylamino hydroxamic acid derivatives
CA2279863A1 (en) 1997-02-07 1998-08-13 Pfizer Inc. N-hydroxy-beta-sulfonyl-propionamide derivatives and their use as inhibitors of matrix metalloproteinases
CA2280151C (en) 1997-02-11 2005-12-13 Pfizer Inc. Arylsulfonyl hydroxamic acid derivatives
UA73073C2 (uk) 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
DE69826662T2 (de) 1997-07-01 2005-02-17 Warner-Lambert Co. Llc 4-brom or 4-iod-phenylamino-benzhydroxamsäurederivate und ihre anwendung als mek-inhibitoren
US6506798B1 (en) * 1997-07-01 2003-01-14 Warner-Lambert Company 4-Arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective MEK inhibitors
NZ501277A (en) 1997-07-01 2002-12-20 Warner Lambert Co -2(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors
US6310060B1 (en) 1998-06-24 2001-10-30 Warner-Lambert Company 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors
US6821963B2 (en) * 1997-07-01 2004-11-23 Warner-Lambert Company 4-Bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors
GB9725782D0 (en) 1997-12-05 1998-02-04 Pfizer Ltd Therapeutic agents
GB9801690D0 (en) 1998-01-27 1998-03-25 Pfizer Ltd Therapeutic agents
PA8469401A1 (es) 1998-04-10 2000-05-24 Pfizer Prod Inc Derivados biciclicos del acido hidroxamico
PA8469501A1 (es) 1998-04-10 2000-09-29 Pfizer Prod Inc Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico
US6534503B1 (en) 1998-04-28 2003-03-18 Lion Bioscience Ag Melanocortin receptor-3 ligands to treat sexual dysfunction
AUPP616498A0 (en) 1998-09-25 1998-10-15 University Of Queensland, The Synthesis of cyclic peptides
EP1140067A1 (en) 1999-01-07 2001-10-10 Warner-Lambert Company Antiviral method using mek inhibitors
BR9916785A (pt) * 1999-01-07 2001-10-23 Warner Lambert Co Tratamento de asma com inibidores mek
HK1041697A1 (zh) * 1999-01-13 2002-07-19 沃尼尔‧朗伯公司 苯并杂环和它们作为mek抑制剂的用途
WO2000042002A1 (en) 1999-01-13 2000-07-20 Warner-Lambert Company Sulphohydroxamic acids and sulphohydroxamates and their use as mek inhibitors
JP2000204077A (ja) 1999-01-13 2000-07-25 Warner Lambert Co ジアリ―ルアミン
JP2002534446A (ja) 1999-01-13 2002-10-15 ワーナー−ランバート・カンパニー ４′ヘテロアリールジアリールアミン
AP2001002225A0 (en) 1999-01-13 2001-09-30 Warner Lambert Co 1-heterocycle substituted diarylamines.
WO2000042003A1 (en) 1999-01-13 2000-07-20 Warner-Lambert Company Benzenesulfonamide derivatives and their use as mek inhibitors
CA2348236A1 (en) 1999-01-13 2000-07-20 Stephen Douglas Barrett 4-arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective mek inhibitors
GB9910577D0 (en) 1999-05-08 1999-07-07 Zeneca Ltd Chemical compounds
GB9912961D0 (en) 1999-06-03 1999-08-04 Pfizer Ltd Metalloprotease inhibitors
PL352684A1 (pl) 1999-07-16 2003-09-08 Warner-Lambert Company Sposób leczenia chronicznego bólu z użyciem inhibitorów MEK
US7030119B1 (en) * 1999-07-16 2006-04-18 Warner-Lambert Company Method for treating chronic pain using MEK inhibitors
JP2003504398A (ja) * 1999-07-16 2003-02-04 ワーナー−ランバート・カンパニー Ｍｅｋ阻害剤を用いた慢性疼痛の治療方法
EP1202732A2 (en) 1999-07-16 2002-05-08 Warner-Lambert Company Llc Method for treating chronic pain using mek inhibitors
PL352712A1 (en) 1999-07-16 2003-09-08 Warner-Lambert Company Method for treating chronic pain using mek inhibitors
WO2001021634A1 (en) 1999-09-21 2001-03-29 Lion Bioscience Ag Benzimidazole derivatives and combinatorial libraries thereof
MXPA02008103A (es) 2000-03-15 2002-11-29 Warner Lambert Co Diarilaminas sustituidas con 5-amida como inhibidores mek.
EP1339702A1 (en) 2000-03-15 2003-09-03 Warner-Lambert Company 5-amide substituted diarylamines as mek inhibitors
AP2003002742A0 (en) 2000-07-19 2003-03-31 Warner Lambert Co Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids
IL154507A0 (en) 2000-08-25 2003-09-17 Warner Lambert Co Process for making n-aryl-anthranilic acids and their derivatives
WO2002044166A1 (en) 2000-11-02 2002-06-06 Astrazeneca Ab Substituted quinolines as antitumor agents
EP1341768A1 (en) 2000-12-07 2003-09-10 AstraZeneca AB Therapeutic benzimidazole compounds
US7102009B2 (en) 2001-01-12 2006-09-05 Amgen Inc. Substituted amine derivatives and methods of use
CA2440438C (en) 2001-03-09 2011-05-03 Ortho-Mcneil Pharmaceutical, Inc. Heterocyclic compounds
US20040039208A1 (en) 2001-07-20 2004-02-26 Chen Michael Huai Gu Process for making n-aryl-anthranilic acids and their derivatives
EP1427408A4 (en) 2001-09-17 2005-10-26 Bristol Myers Squibb Co CYCLIC HYDROXAMINE ACIDS AS INHIBITORS OF MATRIX METALLOPROTEINASES AND / OR TNF-a-CONVERTASE (TACE TNF-a-CONVERTING ENZYM)
AU2002348791A1 (en) 2001-12-21 2003-07-09 Warner-Lambert Company Llc Modified mek1 and mek2, crystal of a peptide: ligand: cofactor complex containing such modified mek1 or mek2, and methods of use thereof
BR0307060A (pt) * 2002-01-23 2004-10-26 Warner Lambert Co ésteres hidroxamato do ácido n-(fenil 4-substituìdo)-antranìlico
PL230179B1 (pl) * 2002-03-13 2018-09-28 Array Biopharma Inc N3 Alkilowane pochodne benzoimidazolu, kompozycja je zawierająca oraz ich zastosowanie do wytwarzania leku do leczenia zaburzeń hiperproliferacyjnych
US7235537B2 (en) 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
TW200406203A (en) * 2002-03-13 2004-05-01 Array Biopharma Inc N3 alkylated banzimidazole derivatives as MEK inhibitors
DE10238002A1 (de) 2002-08-20 2004-03-04 Merck Patent Gmbh Benzimidazolderivate
EP1545532A2 (en) 2002-09-06 2005-06-29 Janssen Pharmaceutica N.V. Heterocyclic compounds
US20040127395A1 (en) 2002-09-06 2004-07-01 Desai Pragnya J. Use of histamine H4 receptor modulators for the treatment of allergy and asthma
US7582635B2 (en) 2002-12-24 2009-09-01 Purdue Pharma, L.P. Therapeutic agents useful for treating pain
EP1651214B1 (en) 2003-07-24 2009-09-16 Warner-Lambert Company LLC Benzimidazole derivatives as mek inhibitors
DE102005032379A1 (de) 2005-07-08 2007-01-11 Conti Temic Microelectronic Gmbh Zugangskontrollsystem für ein Kraftfahrzeug
TWI405756B (zh) 2005-12-21 2013-08-21 Array Biopharma Inc 新穎硫酸氫鹽
US9867825B2 (en) 2012-12-20 2018-01-16 Novartis Ag Pharmaceutical combination comprising binimetinib

Also Published As

Publication number Publication date
IS2990B (is) 2017-12-15
CN101486682B (zh) 2013-08-14
IS2748B (is) 2011-08-15
TWI350285B (en) 2011-10-11
EP3000810A1 (en) 2016-03-30
US7576114B2 (en) 2009-08-18
AU2009222613A1 (en) 2009-10-29
IL204419A0 (en) 2011-07-31
US7425637B2 (en) 2008-09-16
PT2275102E (pt) 2015-10-27
IL163995A (en) 2010-11-30
ES2549159T3 (es) 2015-10-23
RU2004127926A (ru) 2005-06-27
IS2998B (is) 2018-06-15
US8193231B2 (en) 2012-06-05
CL2012002380A1 (es) 2012-11-05
AU2003218157B2 (en) 2009-07-09
US8193229B2 (en) 2012-06-05
AR090143A2 (es) 2014-10-22
HUE025767T2 (en) 2016-05-30
PL377628A1 (pl) 2006-02-06
PA8569301A1 (es) 2004-10-08
NL300974I2 (nl) 2022-04-06
CY1119136T1 (el) 2018-02-14
ES2407849T3 (es) 2013-06-14
PL401638A1 (pl) 2013-05-27
CN100519539C (zh) 2009-07-29
US20050143438A1 (en) 2005-06-30
US20100267710A1 (en) 2010-10-21
DE60330227D1 (de) 2010-01-07
HK1141976A1 (en) 2010-11-26
IS8961A (is) 2011-06-16
CY2019012I1 (el) 2020-05-29
US20100261718A1 (en) 2010-10-14
IS7442A (is) 2004-09-09
JP5102642B2 (ja) 2012-12-19
LTC1482932I2 (lt) 2020-04-27
IL204420A (en) 2012-12-31
SI2130537T1 (sl) 2013-01-31
KR20100040759A (ko) 2010-04-20
US20120277277A1 (en) 2012-11-01
PT3000810T (pt) 2017-10-25
IL204420A0 (en) 2011-07-31
EP2130536B1 (en) 2013-05-08
PT2130537E (pt) 2012-12-20
BR122018007328B8 (pt) 2021-05-25
DK1482932T3 (da) 2010-02-01
HUS1900011I1 (hu) 2019-04-29
ATE449605T1 (de) 2009-12-15
JP5498546B2 (ja) 2014-05-21
US20080177082A1 (en) 2008-07-24
AU2003218157A1 (en) 2003-09-29
TWI338685B (en) 2011-03-11
AR038971A1 (es) 2005-02-02
ES2335276T3 (es) 2010-03-24
HK1070823A1 (en) 2005-06-30
EP2130537B1 (en) 2012-11-14
ES2635666T3 (es) 2017-10-04
JP2008163034A (ja) 2008-07-17
KR20040094786A (ko) 2004-11-10
US20030232869A1 (en) 2003-12-18
IS8959A (is) 2011-06-16
CN101633645A (zh) 2010-01-27
US7973170B2 (en) 2011-07-05
RU2307831C9 (ru) 2008-06-10
EP3000810B1 (en) 2017-07-19
TW200407129A (en) 2004-05-16
EP1482932A1 (en) 2004-12-08
US20110158971A1 (en) 2011-06-30
EP2130536A1 (en) 2009-12-09
IS2999B (is) 2018-06-15
US8193230B2 (en) 2012-06-05
JP4093966B2 (ja) 2008-06-04
PL401637A1 (pl) 2013-05-27
DK2275102T3 (en) 2015-11-02
PT1482932E (pt) 2010-01-12
EP2275102A1 (en) 2011-01-19
CN101633645B (zh) 2011-06-22
NZ535158A (en) 2007-06-29
ZA200407220B (en) 2007-05-30
KR100984613B1 (ko) 2010-09-30
SG148857A1 (en) 2009-01-29
PL401635A1 (pl) 2013-05-27
KR20100040760A (ko) 2010-04-20
UA77765C2 (en) 2007-01-15
CA2478374A1 (en) 2003-09-25
SG194238A1 (en) 2013-11-29
PL401636A1 (pl) 2013-05-27
US20100261717A1 (en) 2010-10-14
FR19C1014I1 (fr) 2019-04-19
KR100984573B1 (ko) 2010-09-30
BE2019C510I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2022-05-19
DOP2013000023A (es) 2013-06-30
LTPA2019007I1 (lt) 2019-03-25
SG2013013339A (en) 2014-12-30
US20100260714A1 (en) 2010-10-14
TW201031641A (en) 2010-09-01
JP2008019277A (ja) 2008-01-31
AR090144A2 (es) 2014-10-22
SI1482932T1 (sl) 2010-02-26
PL233493B1 (pl) 2019-10-31
EP1482932A4 (en) 2006-04-05
TWI343377B (en) 2011-06-11
CN101633644B (zh) 2012-05-09
DOP2011000109A (es) 2011-11-30
HK1153139A1 (en) 2012-03-23
CA2478374C (en) 2009-01-06
US7777050B2 (en) 2010-08-17
CN101633644A (zh) 2010-01-27
SI2275102T1 (sl) 2015-12-31
EP2130537A1 (en) 2009-12-09
CY1109727T1 (el) 2014-09-10
ES2394347T3 (es) 2013-01-30
EP1482932B1 (en) 2009-11-25
BR122018007328B1 (pt) 2020-03-03
US20080171778A1 (en) 2008-07-17
CN1652776A (zh) 2005-08-10
US8178693B2 (en) 2012-05-15
US8003805B2 (en) 2011-08-23
CN101486682A (zh) 2009-07-22
DOP2003000613A (es) 2003-09-30
FR19C1014I2 (fr) 2020-03-13
DOP2011000110A (es) 2011-11-30
TW201031642A (en) 2010-09-01
KR100984595B1 (ko) 2010-09-30
CY2019012I2 (el) 2020-05-29
LUC00100I1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2019-02-13
LUC00100I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2020-01-23
PL233177B1 (pl) 2019-09-30
IL204419A (en) 2012-12-31
IL163995A0 (en) 2005-12-18
DK2130537T3 (da) 2013-02-18
MXPA04008893A (es) 2005-06-20
RU2307831C2 (ru) 2007-10-10
CL2012002381A1 (es) 2012-11-05
JP2005530709A (ja) 2005-10-13
DK3000810T3 (en) 2017-10-16
AU2009222613B2 (en) 2011-06-16
US8513293B2 (en) 2013-08-20
IS8960A (is) 2011-06-16
EP2275102B1 (en) 2015-07-29
SI3000810T1 (sl) 2017-10-30
US20100267793A1 (en) 2010-10-21
JP2012224649A (ja) 2012-11-15
AU2003218157C1 (en) 2011-11-24
WO2003077914A1 (en) 2003-09-25

Similar Documents

Publication Publication Date Title
PL230179B1 (pl) N3 Alkilowane pochodne benzoimidazolu, kompozycja je zawierająca oraz ich zastosowanie do wytwarzania leku do leczenia zaburzeń hiperproliferacyjnych
US7842816B2 (en) N3 alkylated benzimidazole derivatives as MEK inhibitors
ZA200402467B (en) Mechanical reinforcement to improve high current, short duration withstand of a monolithic disk or bonded disk stack
BRPI0306026B1 (pt) Composto, composição farmaceutica e uso de um composto
HK1153139B (en) N3 alkylated benzimidazole derivatives as mek inhibitors